Bristol-Myers Squibb Stock: A Strong Buy Amid Oncology Success

Group 1 - Bristol-Myers Squibb (NYSE: BMY) reported financial results for Q4 2024, exceeding Wall Street analysts' expectations for the fourth consecutive quarter [1] Group 2 - Allka Research has over two decades of experience in investment, focusing on uncovering undervalued assets in ETFs, commodities, technology, and pharmaceutical sectors [2] - The firm aims to simplify investment strategies and empower both seasoned and novice investors through its analyses and insights [2] - Allka Research contributes to the Seeking Alpha community by providing thought-provoking analyses and fostering a community of informed investors [2]